Erectile Dysfunction Drugs Market Growth, Size, Trends Analysis - By Product, By Mode of Administration - Regional Outlook, Competitive Strategies and Segment Forecast to 2034

Description

Erectile Dysfunction Drugs Market Introduction and Overview

According to SPER market research, 'Globa Erectile Dysfunction Drugs Market Size- By Product, By Mode of Administration l - Regional Outlook, Competitive Strategies and Segment Forecast to 2034' state that the Global Erectile Dysfunction Drugs Market is predicted to reach 7.44 billion by 2034 with a CAGR of 9.44%.

Erectile dysfunction (ED) drugs are medications used to treat the condition of erectile dysfunction, which is the inability to obtain or sustain an erection long enough for sexual intercourse. Erectile dysfunction medicines operate by increasing blood flow to the penis, allowing an erection to form and be maintained. The most prevalent erectile dysfunction medications are phosphodiesterase type 5 (PDE5) inhibitors, such as sildenafil (Viagra), tadalafil (Cialis), and vardenafil (Levitra).

Restraints: The various adverse effects associated with erectile dysfunction treatments limit their use and have a negative impact on market growth. For example, common adverse effects of erectile dysfunction medications include headaches, face flushing, and back pain. However, serious adverse effects include loss of vision, loss of hearing, and a painful erection lasting more than four hours. On the other side, erectile drugs can interact with other prescriptions, such as nitrates, resulting in a significant reduction in blood pressure.

Scope of the Report:

Report Metric Details

Market size available for years 2021-2034

Base year considered 2024

Forecast period 2025-2034

Segments covered By Product, By Mode of Administration.

Regions covered

North America, Latin America, Asia-Pacific, Europe, and Middle East & Africa.

Companies Covered

Bayer AG, Lilly, GlaxoSmithKline PLC, Petros Pharmaceuticals, Inc, Pfizer Inc, Teva Pharmaceutical, Lupin Limited, Futura Medical, Cure Pharmaceutical, 23andMe, Hims & Hers Health, Inc.

Erectile Dysfunction Drugs Market Segmentation:

By Product: Based on the Product, Global Erectile Dysfunction Drugs Market is segmented as; Viagra, Cialis, Levitra/Staxyn, Stendra/Spedra, Zydena, Other Drugs.

By Route of Administration: Based on the Route of Administration, Global Erectile Dysfunction Drugs Market is segmented as; Oral Mode of Administration, Injectable Mode of Administration, Other Modes of Administration.

By Region: This research also includes data for North America, Latin America, Asia-Pacific, Europe, Middle East & Africa.

Product Code: PHAR2502

1. Introduction

1.1. Scope of the report
1.2. Market segment analysis

2. Research Methodology

2.1. Research data source
- 2.1.1. Secondary Data
- 2.1.2. Primary Data
- 2.1.3. SPERs internal database
- 2.1.4. Premium insight from KOLs
2.2. Market size estimation
- 2.2.1. Top-down and Bottom-up approach
2.3. Data triangulation

3. Executive Summary

4. Market Dynamics

4.1. Driver, Restraint, Opportunity and Challenges analysis
- 4.1.1. Drivers
- 4.1.2. Restraints
- 4.1.3. Opportunities
- 4.1.4. Challenges

5. Market variable and outlook

5.1. SWOT Analysis
- 5.1.1. Strengths
- 5.1.2. Weaknesses
- 5.1.3. Opportunities
- 5.1.4. Threats
5.2. PESTEL Analysis
- 5.2.1. Political Landscape
- 5.2.2. Economic Landscape
- 5.2.3. Social Landscape
- 5.2.4. Technological Landscape
- 5.2.5. Environmental Landscape
- 5.2.6. Legal Landscape
5.3. PORTERs Five Forces
- 5.3.1. Bargaining power of suppliers
- 5.3.2. Bargaining power of buyers
- 5.3.3. Threat of Substitute
- 5.3.4. Threat of new entrant
- 5.3.5. Competitive rivalry
5.4. Heat Map Analysis

6. Competitive Landscape

6.1. Global Erectile Dysfunction Drugs Market Manufacturing Base Distribution, Sales Area, Product Type
6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Erectile Dysfunction Drugs Market

7. Global Erectile Dysfunction Drugs Market, By Product (USD Million) 2021-2034

7.1. Viagra (sildenafil citrate)
7.2. Cialis (Tadalafil)
7.3. Levitra/Staxyn (vardenafil)
7.4. Stendra/Spedra (avanafil)
7.5. Zydena (udenafil)
7.6. Other Drugs

8. Global Erectile Dysfunction Drugs Market, By Route of Administration (USD Million) 2021-2034

8.1. Oral Mode of Administration
8.2. Injectable Mode of Administration
8.3. Other Modes of Administration

9. Global Erectile Dysfunction Drugs Market, (USD Million) 2021-2034

9.1. Global Erectile Dysfunction Drugs Market Size and Market Share

10. Global Erectile Dysfunction Drugs Market, By Region, (USD Million) 2021-2034

10.1. Asia-Pacific
- 10.1.1. Australia
- 10.1.2. China
- 10.1.3. India
- 10.1.4. Japan
- 10.1.5. South Korea
- 10.1.6. Rest of Asia-Pacific
10.2. Europe
- 10.2.1. France
- 10.2.2. Germany
- 10.2.3. Italy
- 10.2.4. Spain
- 10.2.5. United Kingdom
- 10.2.6. Rest of Europe
10.3. Middle East and Africa
- 10.3.1. Kingdom of Saudi Arabia
- 10.3.2. United Arab Emirates
- 10.3.3. Qatar
- 10.3.4. South Africa
- 10.3.5. Egypt
- 10.3.6. Morocco
- 10.3.7. Nigeria
- 10.3.8. Rest of Middle-East and Africa
10.4. North America
- 10.4.1. Canada
- 10.4.2. Mexico
- 10.4.3. United States
10.5. Latin America
- 10.5.1. Argentina
- 10.5.2. Brazil
- 10.5.3. Rest of Latin America

11. Company Profile

11.1. Bayer AG
- 11.1.1. Company details
- 11.1.2. Financial outlook
- 11.1.3. Product summary
- 11.1.4. Recent developments
11.2. Lilly
- 11.2.1. Company details
- 11.2.2. Financial outlook
- 11.2.3. Product summary
- 11.2.4. Recent developments
11.3. GlaxoSmithKline PLC
- 11.3.1. Company details
- 11.3.2. Financial outlook
- 11.3.3. Product summary
- 11.3.4. Recent developments
11.4. Petros Pharmaceuticals, Inc
- 11.4.1. Company details
- 11.4.2. Financial outlook
- 11.4.3. Product summary
- 11.4.4. Recent developments
11.5. Pfizer Inc
- 11.5.1. Company details
- 11.5.2. Financial outlook
- 11.5.3. Product summary
- 11.5.4. Recent developments
11.6. Teva Pharmaceutical
- 11.6.1. Company details
- 11.6.2. Financial outlook
- 11.6.3. Product summary
- 11.6.4. Recent developments
11.7. Lupin Limited
- 11.7.1. Company details
- 11.7.2. Financial outlook
- 11.7.3. Product summary
- 11.7.4. Recent developments
11.8. Futura Medical
- 11.8.1. Company details
- 11.8.2. Financial outlook
- 11.8.3. Product summary
- 11.8.4. Recent developments
11.9. Cure Pharmaceutical
- 11.9.1. Company details
- 11.9.2. Financial outlook
- 11.9.3. Product summary
- 11.9.4. Recent developments
11.10. Hims & Hers Health, Inc
- 11.10.1. Company details
- 11.10.2. Financial outlook
- 11.10.3. Product summary
- 11.10.4. Recent developments
11.11. Others